NCT04115436 (GSAF) is a clinical trial in Thromboembolic Events, sponsored by Texas Cardiac Arrhythmia Research Foundation.

Who is sponsoring NCT04115436?

NCT04115436 is sponsored by Texas Cardiac Arrhythmia Research Foundation.

What condition does NCT04115436 study?

NCT04115436 studies Thromboembolic Events.

Is NCT04115436 still recruiting?

NCT04115436 is currently status unknown. Last updated 17 October 2019.

Last reviewed 2019-10-17 · How we verify

NCT04115436: GSAF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation

Status unknown Last updated 17 October 2019

What this trial tests

trial in Thromboembolic Events in 40 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Texas Cardiac Arrhythmia Research Foundation
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 October 2019
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across United States

Conditions studied

Thromboembolic Events — all drugs for Thromboembolic Events →

Sponsor

Texas Cardiac Arrhythmia Research Foundation

Who can join

Eligibility, any sex, with Thromboembolic Events. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events. However, some patients are observed to remain stroke-free while off OACs for years whereas others experience TE events if OAC is discontinued even for a short period of time. Therefore, we aim to evaluate the association of genetic variants (single nucleotide polymorphisms - SNPs) with off-anticoagulation stroke-risk in AF patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Texas Cardiac Arrhythmia Research Foundation trials

Trials by the same sponsor.

NCT06488820 — Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Versus Low-volume Ablation Centers (SAFFICI · terminated
NCT04830774 — Natural History of COVID-19-Related Atrial Fibrillation · NA · unknown
NCT04726943 — RF Applications for Residual LAA Leaks · NA · unknown
NCT04502017 — Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial · Phase 4 · unknown
NCT04352764 — ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Health · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04115436 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Texas Cardiac Arrhythmia Research Foundation
Last refreshed: 17 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04115436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing